Key Takeaways
- Spyre Therapeutics reports positive phase 2 results for SPY002, an anti-TL1A antibody targeting ulcerative colitis.
- The drug showed significant reductions in histopathology scores and promising rates for clinical remission and endoscopic improvement.
- The company plans to provide results for SPY003 in Q3, completing the proof-of-concept for its monotherapy candidates.
Developments in Ulcerative Colitis Treatment
Spyre Therapeutics is advancing its competitive strategy in the ulcerative colitis market with promising results from a phase 2 trial of its anti-TL1A antibody, SPY002. The data, part of the Skyline program, encompasses a two-part study focusing on induction and maintenance with three candidates: SPY002, SPY001 (an anti-α4β7 antibody), and SPY003 (an anti-IL23 antibody).
The initial findings from Part A of the trial, which studied a single dose of each candidate, indicated that SPY002 met key objectives. Notably, it achieved a notable 10.7-point reduction in patients’ Robart’s Histopathology Index (RHI) scores by week 12. This scoring method is essential for gauging histological disease activity in ulcerative colitis. Furthermore, secondary measures reported a 33% clinical remission rate and a 42% improvement in endoscopic scores, figures that Spyre characterized as “among the highest reported” in the field.
The safety profile of SPY002 aligns with expectations for the TL1A class. Out of 48 patients, 20 experienced treatment-emergent adverse events, but only two incidents were classified as serious and unrelated to the drug. Dr. Deanna Nguyen, SVP of clinical development at Spyre, emphasized that SPY002’s results are pioneering within its class and support the rationale for developing optimized monotherapy components that could facilitate superior combination therapies.
Analysts from Mizuho recognized SPY002’s efficacy, noting its potential to achieve “unprecedented induction clinical remission rates” when paired with SPY001. In an earlier report, SPY001 had showcased a 9.2-point reduction in RHI scores along with a 40% clinical remission rate and 51% endoscopic improvement in patients, reinforcing its competitive stance against Takeda’s Entyvio, a leading treatment in the same category.
Spyre is progressing with the next phases of its trial, planning to release results for SPY003 during the third quarter, which will provide comprehensive data on its monotherapy approach before moving to combination therapies in Part B of the study. SPY001 and SPY002, designed to enhance treatment efficacy in ulcerative colitis, exemplify Spyre’s commitment to developing novel therapies to address this chronic condition effectively.
The content above is a summary. For more details, see the source article.